PDS Biotechnology Corporation (PDSB) News

PDS Biotechnology Corporation (PDSB): $6.53

-2.89 (-30.68%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add PDSB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#306 of 381

in industry

Filter PDSB News Items

PDSB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PDSB News Highlights

  • For PDSB, its 30 day story count is now at 6.
  • Over the past 21 days, the trend for PDSB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about PDSB are PDS, COMP and MET.

Latest PDSB News From Around the Web

Below are the latest news stories about PDS BIOTECHNOLOGY CORP that investors may wish to consider to help them evaluate PDSB as an investment opportunity.

PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET

FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will be hosting a conference call and webcast tomorrow, June 6, 2023, to discuss the promising interim data from the VERSATILE-002 (NCT04260126) Phase 2 clinical trial investigating PDS0101 in combination with Merck’s anti-PD-1 therapy

Yahoo | June 5, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time for another dive into the biggest pre-market stock movers as we check out what's happening this morning on Friday!

William White on InvestorPlace | May 26, 2023

PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients

Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1%A disease control rate (disease stabilization or tumor shrinkage) of 70.6%Median overall survival not yet met Company to host conference call and webcast on June 6, 2023, at 8:00 am ET FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy comp

Yahoo | May 25, 2023

PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

Company plans to initiate VERSATILE-003 Phase 3 clinical trial in late 2023FLORHAM PARK, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced the completion of enrollment in the immune checkpoint inhibitor naïve group (ICI naïve) of its VERSATILE-002 Phase 2 trial for the treatment of recurrent or metastatic human papi

Yahoo | May 18, 2023

PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2023 Earnings Call Transcript

PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2023 Earnings Call Transcript May 15, 2023 PDS Biotechnology Corporation misses on earnings expectations. Reported EPS is $-0.32 EPS, expectations were $-0.31. Operator: Hello, and welcome to the PDS Biotechnology First Quarter 2023 Earnings Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation. As a […]

Yahoo | May 17, 2023

Q1 2023 PDS Biotechnology Corp Earnings Call

Q1 2023 PDS Biotechnology Corp Earnings Call

Yahoo | May 16, 2023

PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results

Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to host conference call and webcast today, May 15, 2023, at 8:00 AM ET FLORHAM PARK, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, will discuss its financial results for the quarter ended March 31, 2023, and provide a business update on its conference call tod

Yahoo | May 15, 2023

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results

FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will release financial results for the first quarter of 2023 on Monday, May 15, 2023, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.

Yahoo | May 4, 2023

PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients

Abstract selected as featured poster to be reviewed by expert panel in the Head and Neck Cancer discussion sessionFLORHAM PARK, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced the presentation of updated data from the VERSATILE-002 study at the 2023 ASCO® Annual Meeting being held June 2-6 in Chicago. The abstract was

Yahoo | April 27, 2023

PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

FLORHAM PARK, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease announced the Company received $1.4 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company’s participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss (NOL) program for

Yahoo | April 24, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7489 seconds.